enzastaurin has been researched along with Metastase in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birkmann, J; Hanauske, A; Lahn, M; Ohnmacht, U; Smetak, M; Weigang-Koehler, K; Wilhelm, M | 1 |
| Cui, J; Gao, D; Guo, K; Kang, X; Li, Y; Liu, Y; Sun, L | 1 |
| Hristova-Kazmierski, M; Isakoff, SJ; Johnson, C; Krop, I; Miller, KD; Mina, L; Schneider, CJ; Shonukan, OO; Sledge, GW; Vaughn, LG; Wang, Y; Yu, M; Zon, RT | 1 |
| Gonelli, A; Guerrini, R; Mischiati, C; Salvadori, S; Voltan, R; Zauli, G | 1 |
| Asmar, L; Becerra, C; Boehm, KA; Gersh, RH; Gill, JF; Hozak, RR; Kuefler, PR; Mullaney, BP; Myrand, SP; Nicol, SJ; Obasaju, CK; Richards, DA; Wilfong, LS; Zhan, F; Zhao, L | 1 |
| Dreicer, R; Garcia, J; Hussain, M; Kania, M; Raghavan, D; Rini, B; Somer, B; Srinivas, S; Vogelzang, N; Zhao, YD | 1 |
| Allgayer, H; Körner, A; Manegold, C; Mudduluru, G | 1 |
| Di Bartolomeo, M; Fuchs, M; Heinemann, V; Hossain, AM; Nicol, S; Stoffregen, C; Wolff, RA | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
1 review(s) available for enzastaurin and Metastase
| Article | Year |
|---|---|
Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bryostatins; Cell Cycle; Cell Transformation, Neoplastic; Clinical Trials as Topic; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Plant Extracts; Protein Kinase C-delta; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53 | 2009 |
5 trial(s) available for enzastaurin and Metastase
| Article | Year |
|---|---|
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2009 |
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2011 |
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Disease-Free Survival; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2011 |
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Indoles; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Placebos; Retreatment | 2012 |
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |
3 other study(ies) available for enzastaurin and Metastase
| Article | Year |
|---|---|
Reduction of HLA-DR+ lymphocytes after treatment with enzastaurin in patients with metastatic thyroid cancer.
Topics: Antineoplastic Agents; HLA-DR Antigens; Humans; Immunophenotyping; Indoles; Lymphocyte Count; Lymphocytes; Neoplasm Metastasis; Thyroid Neoplasms | 2008 |
Role of PKCbeta in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Humans; Indoles; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Protein Kinase C; Protein Kinase C beta; RNA Interference; Tetradecanoylphorbol Acetate | 2009 |
Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Gene Knockdown Techniques; Humans; Indoles; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleic Acid Hybridization; Reverse Transcriptase Polymerase Chain Reaction | 2010 |